



ASX Announcement | 17 November 2020  
Noxopharm Limited (ASX:NOX)

## Noxopharm Annual General Meeting Results

**Sydney, 17 November 2020:** Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

***All resolutions were passed and decided by way of a poll.***

*Graham Kelly, Noxopharm CEO and Managing Director, has approved the release of this document to the market on behalf of the Board of Directors.*

**-ENDS-**

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling as a second-generation immuno-oncology drug in various forms of late-stage cancer.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

### **Investor & Corporate enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

### **Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Media Enquiries**

Julia Maguire  
The Capital Network  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)  
T: + 61 2 8999 3699

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

## NOXOPHARM LIMITED

Annual General Meeting

Tuesday, 17 November 2020



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of the Remuneration Report	P	24,209,651	19,476,136 80.45%	3,017,808 12.47%	4,521,650	1,715,707 7.09%	21,401,843 87.64%	3,017,808 12.36%	41,010,756
2 Re-election of Graham Kelly as Director	P	28,451,301	27,772,920 97.62%	0 0.00%	280,000	678,381 2.38%	65,150,407 100.00%	0 0.00%	280,000
3 Re-election of Frederik Bart as Director	P	28,591,301	25,461,720 89.05%	2,811,200 9.83%	140,000	318,381 1.11%	62,479,207 95.69%	2,811,200 4.31%	140,000
4 Re-election of Boris Patkin as Director	P	27,961,301	23,412,849 83.73%	2,850,000 10.19%	770,000	1,698,452 6.07%	61,810,407 95.59%	2,850,000 4.41%	770,000
5 Approval of 10% Capacity to issue equity securities	P	28,591,301	26,672,424 93.29%	80,425 0.28%	140,000	1,838,452 6.43%	65,209,982 99.88%	80,425 0.12%	140,000
6 Approval of Issue of Shares to related party of Frederik Bart, Director related to Amended Loan Agreement	P	26,040,839	22,828,833 87.67%	3,033,625 11.65%	2,690,462	178,381 0.69%	59,706,320 95.16%	3,033,625 4.84%	2,690,462
7 Approval of Issue of Shares to Link related to Amended Loan Agreement	P	28,579,301	23,855,924 83.47%	3,024,925 10.58%	152,000	1,698,452 5.94%	62,253,482 95.37%	3,024,925 4.63%	152,000



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval of Issue of Shares to Goodridge Investments related to Amended Loan Agreement	P	18,851,312	14,130,435 74.96%	3,022,425 16.03%	9,879,989	1,698,452 9.01%	52,527,993 94.56%	3,022,425 5.44%	9,879,989
9 Approval of Issue of Incentive Options to Frederik Bart, Director	P	26,040,839	22,809,078 87.59%	3,053,380 11.73%	2,690,462	178,381 0.69%	59,686,565 95.13%	3,053,380 4.87%	2,690,462
10 Approval of Issue of Incentive Options to Boris Patkin, Director	P	28,089,301	23,348,669 83.12%	3,042,180 10.83%	642,000	1,698,452 6.05%	61,746,227 95.30%	3,042,180 4.70%	642,000

